NASDAQ: CYTK · Life Sciences · 8 alerts · CIK 1061983
Share price
$53.17Close, Nov 16
Market cap
$7.41B
Shares outstanding
139.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cytokinetics Inc filings on SEC EDGAR ↗
Cytokinetics Insider B. Lynne Parshall Sells $274K of Stock
B. Lynne Parshall sold 5,000 shares of Cytokinetics Inc at $54.17 to $55.26 a share (average $54.73) in 2 transactions, worth $274K in total on Nov 9, 2026. Shares held after the trade: 5,784 (-30.6%).
Cytokinetics filed its 10-Q for the period ending September 30, 2026, reporting 139,303,351 shares of common stock outstanding as of November 2, 2026. The company continues to advance its clinical pipeline, including aficamten and omecamtiv mecarbil, supported by various financing and royalty agreements with Royalty Pharma and Bayer.
Cytokinetics reported Q3 2026 financial results, highlighted by $44.5 million in net product revenue from MYQORZO (aficamten). The company ended the quarter with approximately $1.6 billion in cash and plans to submit a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026.
Term
Q3 2026
“Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company.”
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer
“In the U.S., the launch of MYQORZO continued to build solid momentum and increased velocity with growing adoption across a broadening base of prescribers.”
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer
Cytokinetics EVP Research & Development Fady Ibraham Malik Sells $220K of Stock
Fady Ibraham Malik, EVP Research & Development, sold 3,500 shares of Cytokinetics Inc at $62.93 a share, worth $220K in total on Nov 3, 2026. Shares held after the trade: 153,902 (-2.2%).
Cytokinetics President & CEO Robert I. Blum Sells $471K of Stock
Robert I. Blum, President & CEO, sold 7,500 shares of Cytokinetics Inc at $62.81 a share, worth $471K in total on Nov 2, 2026. Shares held after the trade: 278,544 (-2.6%).
Cytokinetics EVP Research & Development Fady Ibraham Malik Sells $224K of Stock
Fady Ibraham Malik, EVP Research & Development, sold 3,500 shares of Cytokinetics Inc at $64.01 a share, worth $224K in total on Oct 20, 2026. Shares held after the trade: 153,902 (-2.2%).